Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adam Budzikowski

Clinical Cardiac Electrophysiology Brooklyn, NY Medical Doctor

NPI 1790725125 CMS profile 80646

445 Lenox Rd, Suny Dowstate Div. Cardiovascular Medicine Box 1199, Brooklyn, NY 11203

Open in the dashboard

General payments

$259,011

1,131 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$16,658 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Adam Budzikowski of Brooklyn, NY is reported in the CMS Open Payments database as having received $259,011 across 1,131 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $16,658 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20,391 159
2024 General $32,696 188
2023 General $28,411 173
2022 General $55,401 193
2021 General $32,634 164
2020 General $29,225 105
2019 General $60,253 149

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Budzikowski
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Adam Budzikowski were reported at $20,391. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Adam Budzikowski Clinical Cardiac Electrophysiology median Middle half National median
2019 $60,253 $2,361 $585–$8,260 $163
2020 $29,225 $993 $247–$4,351 $114
2021 $32,634 $1,185 $326–$4,739 $132
2022 $55,401 $2,073 $554–$6,789 $149
2023 $28,411 $2,568 $759–$8,159 $160
2024 $32,696 $2,557 $703–$7,403 $164
2025 $20,391 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $144,355 187 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $41,458 87 payments
  3. Biotronik Inc. $17,184 139 payments
  4. Abbott Laboratories $12,532 167 payments
  5. Scpharmaceuticals Inc. $11,104 18 payments
  6. CVRx, Inc. $7,204 42 payments
  7. Medtronic Vascular, Inc. $5,275 45 payments
  8. CardioFocus, Inc. $4,627 8 payments
  9. Boston Scientific Corporation $3,688 145 payments
  10. Kestra Medical Technology Services, Inc. $2,178 27 payments
  11. Other $9,405 266 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $183,035 118 payments
  2. Food and Beverage $41,817 924 payments
  3. Travel and Lodging $25,886 51 payments
  4. Consulting Fee $3,450 3 payments
  5. Honoraria $2,800 1 payment
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,300 1 payment
  7. Education $722 33 payments
Products named General payments · program years 2019–2025
  1. XARELTO $144,355 187 payments
  2. LifeVest $41,458 87 payments
  3. FUROSCIX $11,104 18 payments
  4. Barostim Neo System $7,204 42 payments
  5. Solia $6,759 30 payments
  6. Selectra $4,520 6 payments
  7. Acticor 7 VR-T DX $3,550 25 payments
  8. AVEIR $3,155 18 payments
  9. BioMonitor $2,670 30 payments
  10. Arctic Front $2,143 11 payments
  11. Other $36,161 751 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 106 drugs

Part D claims

6,389

Median for Cardiology: 2,533

Drug cost

$2,604,063

Median for Cardiology: $485,213

Branded share of claims

42.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 384 $506,990
Xarelto Rivaroxaban Brand 331 $426,757
Eliquis Apixaban Brand 251 $299,307
Farxiga Dapagliflozin Propanediol Brand 261 $280,485
Jardiance Empagliflozin Brand 180 $235,502
Furoscix Furosemide Brand 25 $158,644
Synjardy Empagliflozin/Metformin Hcl Brand 101 $142,083
Mounjaro Tirzepatide Brand 93 $138,958
Multaq Dronedarone Hcl Brand 68 $114,778
Ozempic Semaglutide Brand 38 $47,413

The 10 drugs with the highest cost, of 106 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 101 billing codes

Paid by Medicare

$385,297

Of which drugs: $5,615

Medicare patients

579

Average age 74

Services billed

6,102

283 women, 296 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 64%
Ischemic heart disease 53%
Arthritis 52%
Heart failure 49%
Chronic kidney disease 37%
Atrial fibrillation 36%
Depression 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 11 41 $32

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FUROSCIX
$8,126 25 —
XARELTO
$8,077 331 —
JARDIANCE
$272 180 —
MULTAQ
$138 68 —
FARXIGA
$99 261 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

1,131 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record